Table 2.

Allergic rhinitis (AR) progression (measured as the intensity of AR medication use) in the SLIT and non‐AIT groups over the follow‐up period: regression coefficients; 95% confidence intervals (CI) and P‐values of the factors included in the linear regression model

Factors	Regression coefficient	95% CI	P‐value
Intercept	0.358	0.305‐0.41	<.001
SLIT treatment (vs control)	−0.188	−0.222 to −0.155	<.001
Age <18 y (vs age 18+ y)	−0.127	−0.145 to −0.11	<.001
Male (vs unknown)	−0.081	−0.092 to −0.07	<.001
Female (vs unknown)	−0.056	−0.067 to −0.045	<.001
ENT specialist (vs GP)	−0.037	−0.047 to −0.028	<.001
Dermatologist (vs GP)	−0.075	−0.106 to −0.043	<.001
Pneumologist (vs GP)	−0.025	−.055 to 0.005	.105
Paediatrician (vs GP)	−0.045	−0.074 to −0.015	.003
Internal specialist (vs GP)	0.003	−0.011 to 0.016	.690
Other speciality (vs GP)	0.204	0.163‐0.244	<.001
With asthma before index (vs no asthma)	0.035	0.027‐0.043	<.001
Number of years SLIT treatment (p.a.)	0.037	0.011‐0.062	.005

AIT, allergen immunotherapy; SLIT, sublingual immunotherapy.